Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.
Naito Y, Nakamura S, Kawaguchi-Sakita N, Ishida T, Nakayama T, Yamamoto Y, Masuda N, Matsumoto K, Kogawa T, Sudo K, Shimomura A, Lai C, Zhang D, Iwahori Y, Gary D, Huynh D, Iwata H.
Naito Y, et al. Among authors: nakayama t.
Int J Clin Oncol. 2024 Sep 20. doi: 10.1007/s10147-024-02589-x. Online ahead of print.
Int J Clin Oncol. 2024.
PMID: 39302614